Kintampo Health Research Center
Kintampo, Ghana
NCT Number: NCT03510286
This evaluation will aim to generate a body of evidence that will determine performance characteristics of the current PrCr dipstick test and the feasibility of its use in target ANC settings. Data will be used to inform further product development and/or support development of an introduction framework, including the process and associated resources needed for incorporation of the PrCr test into future larger-scale demonstration studies as well as to support early product launch.
The objectives of the evaluation are as follows:
Primary objective: Assess the accuracy of the PrCr dipstick test for detection of proteinuria in representative antenatal care settings in Ghana.
Exploratory objectives:
* Understand the feasibility of integrating the use of the PrCr test into ANC services in Ghana. * Explore the potential for improved ANC management of PE/E using the PrCr test in intended ANC settings versus the current standard of care used for proteinuria screening, protein-only determination via a low -cost urine dipstick test.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Kintampo, Ghana
This cross-sectional diagnostic accuracy evaluation will employ mixed methods to assess the performance of the PrCr dipstick test and to explore the operational feasibility of using this test as an alternative to the current protein-only test. These methods include:
Assess the accuracy of the PrCr test for detection of proteinuria in a representative ANC setting in Ghana.
Understand the feasibility of integrating the use of the PrCr test into ANC services.
Explore the potential for improved ANC management of PE/E using the PrCr test in the intended ANC setting.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The LifeAssay Diagnostics prototype PrCr dipstick has been designed to provide the measurement of both protein and creatinine while retaining a very low estimated cost that is comparable to the current protein-only dipsticks at $0.06-0.10 per test. In 2015, an initial laboratory-based validation study of the prototype LAD PrCr test was used on more than 500 characterized urine samples from pregnant women. This validation study demonstrated comparable accuracy for detection of severe proteinuria of the LAD PrCr test to the much more expensive commercial POC test available for PrCr determination, the Siemens Multistix® PRO 10LS. These results were compared to laboratory-based reference standard assays for proteinuria measurement.
Time frame: September 20198-February 2019
The results of the PrCr dipstick test will be compared to the results of a laboratory reference assay. Sensitivity and specificity analyses will be conducted at thresholds for normal and proteinuria.
Time frame: September 20198-February 2019
The results of the PrCr dipstick test will be compared to the results of the protein only test. Sensitivity and specificity analyses will be conducted at thresholds for normal and proteinuria.
PATH
Other
Validation of a Protein Creatinine (PrCr) Dipstick Diagnostic Test for Proteinuria Screening in Antenatal Care Clinics in Ghana
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02780414
Blood Platelet Disorders, Cardiovascular Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT01967355
Cardiovascular Diseases, Dyslipidemia
Freiburg im Breisgau, Baden-Wurttemberg, Germany
View Trial DetailsNCT01828138
Cardiovascular Diseases, Female Urogenital Diseases
Skejby, Aarhus, Denmark
View Trial DetailsNCT00654771
Cardiovascular Diseases, Female Urogenital Diseases
Pittsburgh, Pennsylvania, United States
View Trial Details